11. November 2014
TG2 panel from animal species relevant as models for non-clinical safety testing

28. October 2014
Zedira communication: Zedira to present at BioEurope® 2014: License opportunities in celiac disease and anticoagulation

17. September 2014
Zedira supports the Meeting of American Society of Matrix Biology

31. July 2014
Factor XIIIa inhibitor - Transglutaminase newsletter July-2014

18. July 2014
Zedira communication: Publication on MTG Treatment in Pasta

04. March 2014
Zedi's transglutaminase crossword puzzle winner is Greg Byrne

03. March 2014
Zedira supports the Transglutaminase Session at the ASPET Annual Meeting at Experimental Biology 2014

21. January 2014
Activated epidermal Transglutaminase (TG3) - Transglutaminase newsletter 1-2014

03. January 2014
Zedira supports Gordon Research Conference on “Transglutaminases in Human Disease Processes: Molecular Dissection of Human Diseases Pathogenesis”


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation